FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study
暂无分享，去创建一个
V. Heinemann | G. Prager | J. Taieb | A. Reinacher-Schick | C. Müller | S. Stintzing | D. Tougeron | M. Karthaus | L. Fischer von Weikersthal | J. Eucker | I. Schwaner | C. Kahl | R. Pihusch | D. Modest | F. Kaiser | K. Heinrich | B. Krammer-Steiner | C. Burkart | Stefan Kasper-Virchow | M. Stauch